

Novo Nordisk acquires platform for cell line development

13 December 2018 | News

The Beacon platform reduces the extensive resources typically required to generate a cell line for commercial production.



Berkeley Lights, Inc. and Novo Nordisk have announced that Novo Nordisk has purchased the Beacon Optofluidic platform to accelerate workflows in cell line development and to use the platform for future protein and antibody discovery.

The Beacon platform reduces the extensive resources typically required to generate a cell line for commercial production by allowing for parallel screening, maintenance and analysis of thousands of cells.

With the platform's fully integrated and programmable workflow, the time expenditure for screening thousands of cells can be consolidated from 12 weeks to five days. Automating this process and combining it with the variety of assays supported by the platform increases efficiencies, reduces overall costs, and provides rich analytical insights into clone characteristics that are not currently available with traditional techniques for cell line development.